EUROPE CRISPR MARKET 2021-2028

Lifesciences | Diagnostic & Biotechnology

EUROPE CRISPR MARKET 2021-2028

Market by Product, Application, Industry Verticals, and Country | Forecast 2021-2028

Request For Customization

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

As per Triton’s report, the CRISPR market in Europe is estimated to observe growth at a compound annual growth rate of 19.43% during the projected phase of 2021-2028.


Report scope can be customized per your requirements. Request For Customization

The countries studied in this market comprise:

•        The United Kingdom

•        Spain

•        Germany

•        Italy

•        France

•        Russia

•        Rest of Europe

In the United Kingdom, the government aims to boost the research and commercialization of gene-edited food and agriculture products. Moreover, the government is seeking guidance on how DEFRA should reform existing regulations governing organisms produced using genetic technologies. Furthermore, the country has vastly resisted the commercialization of gene technologies in food products, owing to safety and environmental concerns. Nevertheless, the rising research and development of technologies will highlight the use of CRISPR in the agriculture sector. Hence, these factors are likely to create new opportunities for the CRISPR market.

On the other hand, partnerships among leading companies are resulting in innovation in CRISPR technologies across Germany. For instance, ERS Genomic granted a startup company Vivlion a non-exclusive license to its CRISPR-Cas9 patent portfolio to improve gene-editing screening services. Additionally, earlier, the EU science community put significant pressure on regulators to reform the genetic engineering law. Therefore, such steps to develop CRISPR technologies are widening the scope and growth of the CRISPR market within the country.

Cellectis Bioresearch SAS is a biopharmaceutical company that is engaged in developing adoptive immunotherapies for cancer. In addition, it aims to create a new generation of therapies based on engineered T-cells. Moreover, the company’s product line includes UCART, off-the-shelf, allogeneic products that can be industrialized and standardized with a regular pharmaceutical release. With over 16 years of experience in genome engineering, the company is headquartered in France. 

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1. EUROPE CRISPR MARKET - SUMMARY

2. INDUSTRY OUTLOOK

2.1. IMPACT OF COVID-19 ON CRISPR MARKET

2.2. KEY INSIGHTS

2.2.1. INDUSTRIAL BIOTECH IS THE FASTEST GROWING INDUSTRY VERTICAL

2.2.2. REWRITING OF GENETIC DISORDERS THROUGH GENOME SURGERY

2.2.3. INCREASING USAGE OF PROSPECTIVE APPLICATIONS OF CRISPR TECHNOLOGY

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTES

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. THREAT OF COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR SCORECARD

2.6. LEGAL & REGULATORY OUTLOOK

2.7. PATENT OUTLOOK

2.8. FUNDING OUTLOOK

2.9. KEY IMPACT ANALYSIS

2.9.1. COST

2.9.2. ACCURACY

2.9.3. EASY TO USE

2.10. KEY MARKET STRATEGIES

2.10.1. ACQUISITIONS

2.10.2. PRODUCT LAUNCHES

2.10.3. CONTRACTS & PARTNERSHIPS

2.10.4. BUSINESS EXPANSIONS & DIVESTITURES

2.11. MARKET DRIVERS

2.11.1. GROWING LIFESTYLE-ORIENTED DISEASES

2.11.2. SURGING PREVALENCE OF GENETIC DISEASES

2.12. MARKET CHALLENGES

2.12.1. GROWING ETHICAL ISSUES REGARDING TECHNOLOGY USE

2.12.2. LIKELY MISUSE OF GENE-EDITING TOOL

2.13. MARKET OPPORTUNITIES

2.13.1. ADVANCEMENTS IN GENE-BASED THERAPY IN THE AGRICULTURAL SECTOR

2.13.2. INCREASED NEED FOR CLINICAL TRIALS

2.13.3. RISE IN AWARENESS ABOUT GENE THERAPEUTICS

3. EUROPE CRISPR MARKET OUTLOOK - BY PRODUCT

3.1. PLASMIDS

3.2. VECTORS

3.3. PROTEINS

3.4. DESIGNING TOOLS

3.5. GRNA

3.6. CONTROL KITS

3.7. LIBRARY

3.8. OTHER PRODUCTS

4. EUROPE CRISPR MARKET OUTLOOK - BY APPLICATION

4.1. GENOME EDITING/GENETIC ENGINEERING

4.2. CRISPR PLASMID

4.3. HUMAN STEM CELLS

4.4. GRNA DATABASE/GENE LIBRARY

4.5. CELL LINE ENGINEERING

5. EUROPE CRISPR MARKET OUTLOOK - BY INDUSTRY VERTICALS

5.1. THERAPEUTICS AND DRUG DISCOVERY

5.2. BIOLOGICAL RESEARCH

5.3. AGRICULTURAL BIOTECH

5.4. INDUSTRIAL BIOTECH

6. EUROPE CRISPR MARKET – REGIONAL OUTLOOK

6.1. UNITED KINGDOM

6.2. GERMANY

6.3. FRANCE

6.4. SPAIN

6.5. ITALY

6.6. RUSSIA

6.7. REST OF EUROPE

7. COMPETITIVE LANDSCAPE

7.1. ADDGENE

7.2. CARIBOU BIOSCIENCES INC

7.3. CELLECTIS BIORESEARCH SAS

7.4. CRISPR THERAPEUTICS AG

7.5. EDITAS MEDICINE

7.6. GENSCRIPT

7.7. HORIZON DISCOVERY GROUP

7.8. INTEGRATED DNA TECHNOLOGIES

7.9. INTELLIA THERAPEUTICS

7.10. LONZA GROUP LTD

7.11. NEW ENGLAND BIOLABS

7.12. NOVARTIS INTERNATIONAL AG

7.13. ORIGENE TECHNOLOGIES INC

7.14. PRECISION BIOSCIENCES

7.15. SYNTHEGO CORPORATION

8. RESEARCH METHODOLOGY & SCOPE

8.1. RESEARCH SCOPE & DELIVERABLES

8.2. SOURCES OF DATA

8.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: EUROPE CRISPR MARKET, BY COUNTRY, 2021-2028 (IN $ MILLION)        

TABLE 2: VENDOR SCORECARD        

TABLE 3: REGULATORY FRAMEWORK         

TABLE 4: FUNDING OUTLOOK OF PUBLIC COMPANIES  

TABLE 5: FUNDING OUTLOOK OF PRIVATE COMPANIES

TABLE 6: FUNDING OUTLOOK OF GOVERNMENT ORGANIZATIONS   

TABLE 7: EUROPE CRISPR MARKET, BY PRODUCT, 2021-2028 (IN $ MILLION)        

TABLE 8: EUROPE CRISPR MARKET, BY APPLICATION, 2021-2028 (IN $ MILLION) 

TABLE 9: EUROPE CRISPR MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)           

TABLE 10: EUROPE CRISPR MARKET, BY COUNTRY, 2021-2028 (IN $ MILLION)

List of Figures

FIGURE 1: MARKET ATTRACTIVENESS INDEX       

FIGURE 2: FUNDING SCENARIO SHARE, BY TYPE OF COMPANIES/ORGANIZATION         

FIGURE 3: KEY IMPACT ANALYSIS     

FIGURE 4: EUROPE CRISPR MARKET, BY PRODUCT, 2020 & 2028 (IN %)      

FIGURE 5: EUROPE CRISPR MARKET, BY PLASMIDS, 2021-2028 (IN $ MILLION)     

FIGURE 6: EUROPE CRISPR MARKET, BY VECTORS, 2021-2028 (IN $ MILLION)      

FIGURE 7: EUROPE CRISPR MARKET, BY PROTEINS, 2021-2028 (IN $ MILLION)     

FIGURE 8: EUROPE CRISPR MARKET, BY DESIGNING TOOLS, 2021-2028 (IN $ MILLION)

FIGURE 9: EUROPE CRISPR MARKET, BY GRNA, 2021-2028 (IN $ MILLION)  

FIGURE 10: EUROPE CRISPR MARKET, BY CONTROL KITS, 2021-2028 (IN $ MILLION)      

FIGURE 11: EUROPE CRISPR MARKET, BY LIBRARY, 2021-2028 (IN $ MILLION)      

FIGURE 12: EUROPE CRISPR MARKET, BY OTHER PRODUCTS, 2021-2028 (IN $ MILLION)           

FIGURE 13: EUROPE CRISPR MARKET, BY APPLICATION, 2020 & 2028 (IN %)         

FIGURE 14: EUROPE CRISPR MARKET, BY GENOME EDITING/GENETIC ENGINEERING, 2021-2028 (IN $ MILLION)

FIGURE 15: EUROPE CRISPR MARKET, BY CRISPR PLASMID, 2021-2028 (IN $ MILLION) 

FIGURE 16: EUROPE CRISPR MARKET, BY HUMAN STEM CELLS, 2021-2028 (IN $ MILLION)           

FIGURE 17: EUROPE CRISPR MARKET, BY GRNA DATABASE/GENE LIBRARY, 2021-2028 (IN $ MILLION)   

FIGURE 18: EUROPE CRISPR MARKET, BY CELL LINE ENGINEERING, 2021-2028 (IN $ MILLION)      

FIGURE 19: EUROPE CRISPR MARKET, BY INDUSTRY VERTICALS, 2020 & 2028 (IN %)    

FIGURE 20: EUROPE CRISPR MARKET, BY THERAPEUTICS AND DRUG DISCOVERY, 2021-2028 (IN $ MILLION)          

FIGURE 21: EUROPE CRISPR MARKET, BY BIOLOGICAL RESEARCH, 2021-2028 (IN $ MILLION)      

FIGURE 22: EUROPE CRISPR MARKET, BY AGRICULTURAL BIOTECH, 2021-2028 (IN $ MILLION)      

FIGURE 23: EUROPE CRISPR MARKET, BY INDUSTRIAL BIOTECH, 2021-2028 (IN $ MILLION)           

FIGURE 24: EUROPE CRISPR MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)

FIGURE 25: UNITED KINGDOM CRISPR MARKET 2021-2028 (IN $ MILLION)   

FIGURE 26: GERMANY CRISPR MARKET 2021-2028 (IN $ MILLION)      

FIGURE 27: FRANCE CRISPR MARKET 2021-2028 (IN $ MILLION)          

FIGURE 28: SPAIN CRISPR MARKET 2021-2028 (IN $ MILLION)  

FIGURE 29: ITALY CRISPR MARKET 2021-2028 (IN $ MILLION)   

FIGURE 30: RUSSIA CRISPR MARKET 2021-2028 (IN $ MILLION)           

FIGURE 31: REST OF EUROPE CRISPR MARKET 2021-2028 (IN $ MILLION)    

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;